Prolacta Bioscience
Featured Content
Serving the NICU’s Tiniest Patients
Serving the NICU’s Tiniest Patients: How Human Milk Nutrition Helps Vulnerable Infants Thrive As a proud member of the NICU Parent Network Industry Collective, Prolacta Bioscience is honored to share our commitment to supporting NICU families. Through our role as the...
Learn More About Prolacta
Industry Collective Member
Prolacta Bioscience is dedicated to Advancing the Science of Human Milk to improve the health of critically ill, premature infants. Prolacta’s 100% human milk-based nutritional products have been evaluated in more than 20 clinical studies published in peer-reviewed journals. More than 100,000 premature infants have benefited from Prolacta’s nutritional products worldwide to date.
Established in 1999, Prolacta is the world’s leading provider of human milk-based nutritional products for hospital use and is also exploring the therapeutic potential of human milk across a wide spectrum of diseases. Prolacta maintains the industry’s strictest quality and safety standards for screening, testing, and processing donor human milk. Operating the world’s first pharmaceutical-grade human milk processing facilities, Prolacta uses vat pasteurization and a patented, FDA-reviewed manufacturing process to ensure pathogen inactivation while protecting the nutritional composition and bioactivity of its human milk-based products. Prolacta is a global company with headquarters in Duarte, California.